Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects

Clinical Therapeutics

Volumn 37, Issue 11, 2015, Pages 2489-2505.e2

  Shakeri Nejad, Kasra ^a   Aslanis, Vassilios ^a   Veldandi, Uday Kiran ^b   Mooney, Louise ^a   Pezous, Nicole ^a   Brendani, Bruno ^a   Juan, Axel ^c   Allison, Mark ^d   Perry, Robert ^e   Legangneux, Eric ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Novartis Healthcare Private Limited   (India)

^c SeaView Research Inc   (United States)

^d CELERION   (United States)

^e Elite Research Institute   (United States)

Author keywords

BAF312; cardiac repolarization; healthy subjects; moxifloxacin; siponimod; thorough QT

Indexed keywords

MOXIFLOXACIN; PLACEBO; SIPONIMOD; 1-(4-(1-((E)-4-CYCLOHEXYL-3-TRIFLUOROMETHYLBENZYLOXYIMINO)-ETHYL)-2-ETHYLBENZYL)-AZETIDINE-3-CARBOXYLIC ACID; AZETIDINE DERIVATIVE; BENZYL DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ATRIAL FIBRILLATION; COMPARATIVE STUDY; CONTROLLED STUDY; DENGUE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART REPOLARIZATION; HOLTER MONITORING; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; ST SEGMENT; STEADY STATE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; CHEMICALLY INDUCED; DRUG EFFECTS; ELECTROCARDIOGRAPHY; HEART; HEART RATE; LONG QT SYNDROME; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AZETIDINES; BENZYL COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FLUOROQUINOLONES; HEART; HEART RATE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84947935691     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.09.006     Document Type: Article

References (19)

1. P. Gergely, B. Nuesslein-Hildesheim, D. Guerini, and et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate Br J Pharmacol 167 2012 1035 1047
2. T. Baumruker, A. Billich, and V. Brinkmann FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis Expert Opin Investig Drugs 16 2007 283 289
3. V. Brinkmann, M.D. Davis, C.E. Heise, and et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors J Biol Chem 277 2002 21453 21457
4. J.A. Cohen, F. Barkhof, G. Comi, and et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 2010 402 415
5. L. Kappos, E.W. Radue, P. O'Connor, and et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 2010 387 401
6. K. Selmaj, D.K. Li, H.P. Hartung, and et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study Lancet Neurol 12 2013 756 767
7. M. Matloubian, C.G. Lo, G. Cinamon, and et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 Nature 427 2004 355 360
8. D. Mazurais, P. Robert, B. Gout, and et al. Cell type-specific localization of human cardiac S1P receptors J Histochem Cytochem 50 2002 661 670
9. C.K. Means, and J.H. Brown Sphingosine-1-phosphate receptor signalling in the heart Cardiovasc Res 82 2009 193 200
10. P. Gergely, R. Wallström, B. Nuesslein-Hildesheim, and et al. Phase I study with the selective S1P1/S1P5 receptor modulator BAF312 indicates that S1P1 rather than S1P3 mediates transient heart rate reduction in humans Mult Scler 15 2009 s125 s126
11. E. Legangneux, A. Gardin, and D. Johns Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects Br J Clin Pharmacol 75 2013 831 841
12. R.R. Fenichel, M. Malik, C. Antzelevitch, and et al. Drug-induced torsades de pointes and implications for drug development J Cardiovasc Electrophysiol 15 2004 475 495
13. J. Morganroth Cardiac repolarization and the safety of new drugs defined by electrocardiography Clin Pharmacol Ther 81 2007 108 113
14. D.M. Roden Drug-induced prolongation of the QT interval N Engl J Med 350 2004 1013 1022
15. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals For Human Use. ICH Harmonised Tripartite Guideline: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. May 2005. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E14/E14-Guideline.pdf. Accessed 2015.
16. Food and Drug Administration HHS International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice Fed Regist 70 2005 61134 61135
17. Guidance for Industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073153.pdf. Accessed 2015
18. J.W. Mason, J.A. Florian Jr, C.E. Garnett, and et al. Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies J Clin Pharmacol 50 2010 1249 1259
19. A.R. Magnano, N. Talathoti, R. Hallur, and et al. Sympathomimetic infusion and cardiac repolarization: the normative effects of epinephrine and isoproterenol in healthy subjects J Cardiovasc Electrophysiol 17 2006 983 989